Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma.

Sexton KW, Poteet SP, Hill JB, Schmidt A, Patel A, Del Corral GA, Axt J, Kelley MC, Thayer WP, Shack RB
Ann Plast Surg. 2014 73 (5): 531-4

PMID: 23657045 · DOI:10.1097/SAP.0b013e31827f4c58

Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous malignancy. Adjuvant radiation increases survival in advanced stages, but efficacy in stage I disease is unknown. A retrospective review included all patients treated for stage I MCC during a 15-year period at Vanderbilt University Medical Center. Among 42 patients, 26 (62%) had a negative sentinel lymph node biopsy (stage IA) and 16 (38%) had clinically negative lymph nodes (stage IB) at the time of resection. Analysis using Cox regression revealed that higher stage and absence of adjuvant radiation are associated with increased disease recurrence (hazard ratio, 6.29; P=0.003 and hazard ratio, 4.69; P=0.013, respectively). Controlling for stage, radiation therapy significantly increased disease-free survival among patients with stage IB disease (P=0.0026) in a log-rank test comparing Kaplan-Meier curves. These findings support adjuvant radiation therapy in stage IB MCC patients with clinically negative lymph nodes who do not undergo sentinel lymph node biopsy.

MeSH Terms (23)

Adult Aged Aged, 80 and over Carcinoma, Merkel Cell Disease-Free Survival Extremities Female Follow-Up Studies Head and Neck Neoplasms Humans Kaplan-Meier Estimate Lymphatic Metastasis Lymph Node Excision Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Proportional Hazards Models Radiotherapy, Adjuvant Retrospective Studies Skin Neoplasms Torso Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: